BUSINESS

Cheplapharm Completes Tarceva Transfer, Announces Hydrea Acquisition in Japan

April 3, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

German-based Cheplapharm said on April 1 that it has completed the takeover of the Japanese marketing authorization (MA) for cancer drug Tarceva (erlotinib) from Chugai Pharmaceutical, effective the same day.The transfer of distribution rights for the drug will follow this…

To read the full story

Chugai to Transfer Tarceva to Cheplapharm in April
January 15, 2025

BUSINESS

FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…